BIOMAT Database Logo BIOMAT Database Logo

p21WAF1 expression is associated with improved survival after adjuvant chemoradiation for pancreatic cancer. 2000

S A Ahrendt, and H M Brown, and R A Komorowski, and Y R Zhu, and S D Wilson, and B A Erickson, and P S Ritch, and H A Pitt, and M J Demeure
Department of Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, USA.

BACKGROUND Cell cycle arrest after DNA damage is partly mediated through the transcriptional activation of p21(WAF1) by the p53 tumor suppressor gene. p21(WAF1) and p53 are both critical in maintaining cell cycle control in response to DNA damage from radiation or chemotherapy. Therefore, we examined the role of p21(WAF1) and p53 in the determination of outcome for patients who receive radiation and/or chemotherapy for pancreatic cancer. METHODS p21(WAF1) and p53 protein expression were determined (with the use of immunohistochemistry) in specimens from 90 patients with pancreatic cancer. Forty-four patients underwent surgical resection, and 46 patients had either locally unresectable tumors (n = 9 patients) or distant metastases (n = 37 patients). Seventy-three percent of the patients who underwent resection and 63% of the patients who did not undergo resection received radiation and/or chemotherapy. RESULTS p21(WAF1) expression was present in 48 of 86 tumors (56%) and was significantly (P<.05) associated with advanced tumor stage. Median survival among patients with resected pancreatic cancer who received adjuvant chemoradiation with p21(WAF1)-positive tumors was significantly longer than in patients with no p21(WAF1) staining (25 vs. 11 months; P = .01). Fifty of 89 tumors (56%) stained positive for p53 protein. p53 overexpression was associated with decreased survival in patients who did not undergo resection. CONCLUSIONS Normal p21(WAF1) expression may be necessary for a beneficial response to current adjuvant chemoradiation protocols for pancreatic cancer. Alternate strategies for adjuvant therapy should be explored for patients with pancreatic cancer who lack functional p21(WAF1).

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010180 Pancreatectomy Surgical removal of the pancreas. (Dorland, 28th ed) Pancreatectomies
D010190 Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA). Cancer of Pancreas,Pancreatic Cancer,Cancer of the Pancreas,Neoplasms, Pancreatic,Pancreas Cancer,Pancreas Neoplasms,Pancreatic Acinar Carcinoma,Pancreatic Carcinoma,Acinar Carcinoma, Pancreatic,Acinar Carcinomas, Pancreatic,Cancer, Pancreas,Cancer, Pancreatic,Cancers, Pancreas,Cancers, Pancreatic,Carcinoma, Pancreatic,Carcinoma, Pancreatic Acinar,Carcinomas, Pancreatic,Carcinomas, Pancreatic Acinar,Neoplasm, Pancreas,Neoplasm, Pancreatic,Neoplasms, Pancreas,Pancreas Cancers,Pancreas Neoplasm,Pancreatic Acinar Carcinomas,Pancreatic Cancers,Pancreatic Carcinomas,Pancreatic Neoplasm
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas

Related Publications

S A Ahrendt, and H M Brown, and R A Komorowski, and Y R Zhu, and S D Wilson, and B A Erickson, and P S Ritch, and H A Pitt, and M J Demeure
Adjuvant chemotherapy followed by concurrent chemoradiation is associated with improved survival for resected stage I-II pancreatic cancer.
March 2019, Cancer medicine,
S A Ahrendt, and H M Brown, and R A Komorowski, and Y R Zhu, and S D Wilson, and B A Erickson, and P S Ritch, and H A Pitt, and M J Demeure
Molecular metastases in stage I pancreatic cancer: improved survival with adjuvant chemoradiation.
October 1998, Surgery,
S A Ahrendt, and H M Brown, and R A Komorowski, and Y R Zhu, and S D Wilson, and B A Erickson, and P S Ritch, and H A Pitt, and M J Demeure
The Addition of Chemoradiation to Adjuvant Chemotherapy is Associated With Improved Survival Following Upfront Surgical Resection for Pancreatic Cancer With Nodal Metastases.
January 2022, Cancer control : journal of the Moffitt Cancer Center,
S A Ahrendt, and H M Brown, and R A Komorowski, and Y R Zhu, and S D Wilson, and B A Erickson, and P S Ritch, and H A Pitt, and M J Demeure
Adjuvant Chemotherapy After Neoadjuvant Chemotherapy for Pancreatic Cancer is Associated with Improved Survival for Patients with Low-Risk Pathology.
June 2021, Annals of surgical oncology,
S A Ahrendt, and H M Brown, and R A Komorowski, and Y R Zhu, and S D Wilson, and B A Erickson, and P S Ritch, and H A Pitt, and M J Demeure
Interferon receptor alpha/beta is associated with improved survival after adjuvant therapy in resected pancreatic cancer.
January 2007, HPB : the official journal of the International Hepato Pancreato Biliary Association,
S A Ahrendt, and H M Brown, and R A Komorowski, and Y R Zhu, and S D Wilson, and B A Erickson, and P S Ritch, and H A Pitt, and M J Demeure
Completion of Adjuvant Chemotherapy After Upfront Surgical Resection for Pancreatic Cancer Is Uncommon Yet Associated With Improved Survival.
November 2019, Annals of surgical oncology,
S A Ahrendt, and H M Brown, and R A Komorowski, and Y R Zhu, and S D Wilson, and B A Erickson, and P S Ritch, and H A Pitt, and M J Demeure
Multiagent induction chemotherapy followed by chemoradiation is associated with improved survival in locally advanced pancreatic cancer.
October 2017, Cancer,
S A Ahrendt, and H M Brown, and R A Komorowski, and Y R Zhu, and S D Wilson, and B A Erickson, and P S Ritch, and H A Pitt, and M J Demeure
Gemcitabine and Taxane Adjuvant Therapy with Chemoradiation in Resected Pancreatic Cancer: A Novel Strategy for Improved Survival?
April 2018, Annals of surgical oncology,
S A Ahrendt, and H M Brown, and R A Komorowski, and Y R Zhu, and S D Wilson, and B A Erickson, and P S Ritch, and H A Pitt, and M J Demeure
Survival after chemoradiation in resected pancreatic cancer: the impact of adjuvant gemcitabine.
July 2012, International journal of radiation oncology, biology, physics,
S A Ahrendt, and H M Brown, and R A Komorowski, and Y R Zhu, and S D Wilson, and B A Erickson, and P S Ritch, and H A Pitt, and M J Demeure
The addition of chemoradiation to adjuvant chemotherapy is associated with improved survival in lymph node-positive gastric cancer.
September 2020, Surgical oncology,
Copied contents to your clipboard!